La Jolla Pharmaceutical Company (LJPC)

Etorro trading 970x250
La Jolla Pharmaceutical Company (LJPC) Logo

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California. Address: 4747 Executive Drive, San Diego, CA, United States, 92121

La Jolla Pharmaceutical Company News and around…

Latest news about La Jolla Pharmaceutical Company (LJPC) common stock and company :

Is La Jolla Pharmaceutical Company (LJPC) Going to Burn These Hedge Funds?
04 Oct, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
10 Sep, 2021 FinancialContent

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer.

99 Biggest Movers From Yesterday
06 Aug, 2021 FinancialContent

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn ...

La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates
05 Aug, 2021 Yahoo! Finance

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 184.62% and 34.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
05 Aug, 2021 FinancialContent

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and highlighted corporate progress.

Will La Jolla Pharmaceutical (LJPC) Report Negative Q2 Earnings? What You Should Know
29 Jul, 2021 Yahoo! Finance

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Has Found A Path To Profitability
26 Jul, 2021 Yahoo! Finance

La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) is possibly approaching a major achievement in its business, so we...

What You Need To Know About La Jolla Pharmaceutical Company's (NASDAQ:LJPC) Investor Composition
10 Jun, 2021 Yahoo! Finance

The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Insiders...

46 Stocks Moving In Thursday's Mid-Day Session
03 Jun, 2021 FinancialContent

Gainers GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
03 Jun, 2021 FinancialContent

Gainers Sundial Growers (NASDAQ:SNDL) shares rose 9.73% to $1.24 during Thursday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
03 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into another day of investing and we're starting it off with a look at the biggest pre-market stock movers for Thursday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

28 Stocks Moving in Thursday's Pre-Market Session
03 Jun, 2021 FinancialContent

Gainers GTT Communications, Inc. (NYSE: GTT) rose 41.6% to $3.54 in pre-market trading after jumping over 57% on ...

60 Biggest Movers From Yesterday
27 May, 2021 FinancialContent

Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday. Flywire Corporation (NASDAQ: FLYW) gained ...

Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
18 May, 2021 Yahoo! Finance

La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
07 May, 2021 Yahoo! Finance

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
07 May, 2021 FinancialContent

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress.

Peek Under The Hood: IEIH Has 18% Upside
27 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

How The Parts Add Up: IEIH Headed For $40
24 Mar, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Insiders Increased Their Holdings
11 Mar, 2021 Yahoo! Finance

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
08 Mar, 2021 Yahoo! Finance

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate Progress
08 Mar, 2021 FinancialContent

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress.

Growth Investors: Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
16 Jan, 2021 Yahoo! Finance

La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders will have a reason to smile today, with the analysts...

Top Buys by Directors: Tang's $1.1M Bet on LJPC
14 Jan, 2021 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

70 Biggest Movers From Yesterday
13 Jan, 2021 FinancialContent

Gainers CPS Technologies Corporation (NASDAQ: CPSH) shares climbed 113.8% to close at $6.84 on Tuesday. The company, last week, ...

Notable Tuesday Option Activity: RMBS, LJPC, ZM
12 Jan, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Rambus Inc. (RMBS), where a total of 18,810 contracts have traded so far, representing approximately 1.9 million underlying shares..

12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Jan, 2021 FinancialContent

Gainers Biolase (NASDAQ:BIOL) shares rose 40.29% to $0.81 during Tuesday's regular session. Biolase's stock is ...

52 Stocks Moving In Tuesday's Mid-Day Session
12 Jan, 2021 FinancialContent

Gainers Qilian International Holding Group Ltd (NASDAQ: QLI) shares jumped 76.2% to $8.81 after the company priced its IPO at $5 ...

The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
12 Jan, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Jan, 2021 FinancialContent

Gainers La Jolla Pharmaceutical (NASDAQ:LJPC) shares increased by 61.16% to $6.35 during Tuesday's pre-market ...

La Jolla Pharmaceutical Company (LJPC) is a NASDAQ Common Stock listed in , ,

970x250